Clinical-grade molecular diagnostic tests for hereditary cancer risk, neurodegenerative diseases, drug response, and advanced liquid biopsy.
Targeted bacterial microbiome profiling using 16S rRNA amplicon sequencing
Validated plasma biomarkers for Alzheimer's disease — aligned with NIA-AA 2024 criteria
A comprehensive ASD and neurodevelopmental panel-1,255 SFARI-curated genes
29-gene hereditary breast and ovarian cancer test
Comprehensive hereditary cardiovascular disease panel
NGS virtual panel covering 237 genes across 6 disease panels (Ciliopathies)
31-gene hereditary colorectal cancer test
NGS virtual panel covering 163 genes across 13 disease panels (Dermatological disorders)
Pharmacogenomics for drug personalisation
NGS virtual panel covering 758 genes across 10 disease panels (Dysmorphic and congenital abnormality syndromes)
NGS virtual panel covering 436 genes across 14 disease panels (Endocrine disorders)
34-gene hereditary gastric cancer test
NGS virtual panel covering 312 genes across 6 disease panels (Gastroenterological disorders)
NGS virtual panel covering 36 genes across 2 disease panels (Growth disorders)
NGS virtual panel covering 270 genes across 4 disease panels (Haematological disorders)
NGS virtual panel covering 589 genes across 4 disease panels (Hearing and ear disorders)
NGS virtual panel covering 1001 genes across 9 disease panels (Metabolic disorders)
Neurofibromatosis Genetic testing for NF1 and NF2.
Comprehensive genomic panel for unexplained neurological disorders
NGS virtual panel covering 773 genes across 8 disease panels (Ophthalmological disorders)
123-gene hereditary pan-cancer panel across 10 NCCN-informed subpanels
Hereditary prostate cancer gene panel
NGS virtual panel covering 378 genes across 10 disease panels (Renal and urinary tract disorders)
NGS virtual panel covering 121 genes across 4 disease panels (Respiratory disorders)
NGS virtual panel covering 116 genes across 3 disease panels (Rheumatological disorders)
NGS virtual panel covering 815 genes across 10 disease panels (Skeletal disorders)
Risk stratification for microhaematuria — reduce unnecessary cystoscopy
Non-invasive bladder cancer surveillance — reduce cystoscopy burden in NMIBC
Urine genomic test to risk-stratify haematuria — AUA Guideline Level A Evidence
Minimal residual disease (MRD) detection for early-stage cancer surveillance
Blood-based colorectal cancer screening for average-risk adults age 45+.
First FDA-aproved liquid biopsy for advanced solid tumour treatment guidance
Comprehensive liquid biopsy for advanced solid tumour treatment guidance
Tissue-based comprehensive genomic profiling with digital pathology
Ultra-sensitive blood test for astrocyte injury and neuroinflammation
Universal axonal damage marker for neurodegenerative disease
Validated plasma biomarker for early Alzheimer's disease tau pathology
The most specific blood biomarker for Alzheimer's disease pathology
Highly sensitive detection of misfolded α-synuclein for synucleinopathy diagnosis
Mass spectrometry blood test combining Aβ42/40 and p-tau217 for Alzheimer's diagnosis
shotgun metagenomics for comprehensive microbiome profiling and infectious disease detection